HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

apolipoprotein A-I mimetic peptide 4F

a synthetic peptide that enhances paraoxonase-1 activity

Also Known As:

apoA-I mimetic peptide 4F; peptide 4F

Networked: 13 relevant articles (4 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - apolipoprotein A-I mimetic peptide 4F: 13

Experts

1.	Anantharamaiah, G M: 5 articles (12/2011 - 08/2006)
2.	Datta, Geeta: 4 articles (12/2011 - 08/2006)
3.	White, C Roger: 4 articles (12/2011 - 08/2006)
4.	Reddy, Srinivasa T: 3 articles (12/2021 - 01/2009)
5.	Fogelman, Alan M: 3 articles (08/2014 - 01/2009)
6.	Navab, Mohamad: 3 articles (08/2014 - 01/2009)
7.	Gupta, Himanshu: 3 articles (12/2011 - 08/2006)
8.	Zhang, Zhenghao: 3 articles (12/2011 - 01/2009)
9.	Andrade, Lucia: 2 articles (01/2020 - 09/2014)
10.	Moreira, Roberto S: 2 articles (01/2020 - 09/2014)

Related Diseases

1.	Inflammation (Inflammations) 12/01/2021 - "The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells." 09/01/2014 - "Although the mechanism remains unknown, apolipoprotein A-I (apoA-I) mimetic peptide 4F reduces inflammation and protects HDL levels, which are reduced in sepsis. " 08/01/2006 - "Peptide analogs that have no sequence homology to the domains in apo A-I but possess the class A motif have been shown to not only associate with phospholipid but also mimic several of the functional properties of apo A-I. Peptide 4F, with four phenylalanines on the non-polar face, was found to be maximally effective in mimicking the positive qualities of apo A-I; this peptide inhibited atherosclerosis, reduced inflammation and oxidation, and improved vascular function in a number of animal models, and when synthesized with D-amino acids is orally bioavailable. " 01/01/2009 - "The apoA-I mimetic peptide 4F increased the formation of pre-beta high-density lipoprotein, increased cholesterol efflux, and reduced lipoprotein oxidation in vitro; it increased antioxidants and vascular repair in type 1 diabetic rats; it improved vasodilation, oxidative stress, myocardial inflammation, and angiogenic potential in a mouse model of scleroderma; it reduced renal inflammation in low-density lipoprotein receptor-null mice fed a Western diet; it reduced arthritis in a rat model; it reduced adiposity, increased adiponectin levels, and improved insulin sensitivity in obese mice; and it improved high-density lipoprotein inflammatory properties in humans with coronary heart disease."
2.	Sepsis (Septicemia) 09/01/2014 - "Apolipoprotein A-I mimetic peptide 4F attenuates kidney injury, heart injury, and endothelial dysfunction in sepsis." 09/01/2014 - "Although the mechanism remains unknown, apolipoprotein A-I (apoA-I) mimetic peptide 4F reduces inflammation and protects HDL levels, which are reduced in sepsis. " 08/01/2009 - "Since increasing plasma apolipoprotein A-I (apoA-I) and HDL may reduce the complications of sepsis, we tested the hypothesis that the apoA-I mimetic peptide 4F confers similar protective effects in rats undergoing cecal ligation and puncture (CLP) injury. " 12/22/2011 - "Since raising plasma apolipoprotein (apo) A-I and high density lipoprotein (HDL) concentration reduces sepsis complications, we tested the hypothesis that the apoA-I mimetic peptide 4F confers similar protective effects in rats treated with lipopolysaccharide (LPS). "
3.	Atherosclerosis 08/01/2009 - "Given that apolipoproteinA-1 can limit atherosclerosis, we hypothesized that an apolipoproteinA-1 mimetic peptide, 4F, may reduce the proinflammatory properties of LDL and enhance the anti-inflammatory properties of HDL in uremic plasma. " 01/01/2009 - "Our laboratory has pioneered the development of synthetic, apolipoprotein mimetic peptides which are structurally and functionally similar to apoA-I but possess unique structural homology to the lipid-associating domains of apoA-I. The apoA-I mimetic peptide 4F inhibits atherogenic lesion formation in murine models of atherosclerosis. " 08/01/2006 - "Peptide analogs that have no sequence homology to the domains in apo A-I but possess the class A motif have been shown to not only associate with phospholipid but also mimic several of the functional properties of apo A-I. Peptide 4F, with four phenylalanines on the non-polar face, was found to be maximally effective in mimicking the positive qualities of apo A-I; this peptide inhibited atherosclerosis, reduced inflammation and oxidation, and improved vascular function in a number of animal models, and when synthesized with D-amino acids is orally bioavailable. "
4.	Insulin Resistance 01/01/2009 - "The apoA-I mimetic peptide 4F increased the formation of pre-beta high-density lipoprotein, increased cholesterol efflux, and reduced lipoprotein oxidation in vitro; it increased antioxidants and vascular repair in type 1 diabetic rats; it improved vasodilation, oxidative stress, myocardial inflammation, and angiogenic potential in a mouse model of scleroderma; it reduced renal inflammation in low-density lipoprotein receptor-null mice fed a Western diet; it reduced arthritis in a rat model; it reduced adiposity, increased adiponectin levels, and improved insulin sensitivity in obese mice; and it improved high-density lipoprotein inflammatory properties in humans with coronary heart disease."
5.	Coronary Disease (Coronary Heart Disease) 01/01/2009 - "The apoA-I mimetic peptide 4F increased the formation of pre-beta high-density lipoprotein, increased cholesterol efflux, and reduced lipoprotein oxidation in vitro; it increased antioxidants and vascular repair in type 1 diabetic rats; it improved vasodilation, oxidative stress, myocardial inflammation, and angiogenic potential in a mouse model of scleroderma; it reduced renal inflammation in low-density lipoprotein receptor-null mice fed a Western diet; it reduced arthritis in a rat model; it reduced adiposity, increased adiponectin levels, and improved insulin sensitivity in obese mice; and it improved high-density lipoprotein inflammatory properties in humans with coronary heart disease."

Related Drugs and Biologics

1.	Apolipoprotein A-I (Apolipoprotein A1)
2.	HDL Lipoproteins
3.	Peptides (Polypeptides)
4.	Lipoproteins (Lipoprotein)
5.	Apolipoproteins
6.	Pre-beta High-Density Lipoproteins
7.	Adiponectin
8.	LDL Receptors (LDL Receptor)
9.	Phospholipids (Phosphatides)
10.	Lipopolysaccharides

Related Therapies and Procedures

1.	Punctures
2.	Ligation